<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-6-37</article-id><article-id pub-id-type="pmid">16503999</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-37</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>HFE </italic>H63D mutation frequency shows an increase in Turkish women with breast cancer</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Gunel-Ozcan</surname><given-names>Aysen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>agozcan@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Aly&#x00131;lmaz-Bekmez</surname><given-names>Sibel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alyilmazs@mynet.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Guler</surname><given-names>Emine Nilufer</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>nguler@hacettepe.edu.tr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Guc</surname><given-names>Dicle</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>dguc@hacettepe.edu.tr</email></contrib></contrib-group><aff id="I1"><label>1</label>Kirikkale University School of Medicine, Department of Medical Biology and Genetics, Kirikkale, Turkey</aff><aff id="I2"><label>2</label>Hacettepe University, Oncology Institute, Medical Oncology Department, Ankara, Turkey</aff><aff id="I3"><label>3</label>Hacettepe University, Oncology Institute, Basic Oncology Department, Ankara, Turkey</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>19</day><month>2</month><year>2006</year></pub-date><volume>6</volume><fpage>37</fpage><lpage>37</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/37"/><history><date date-type="received"><day>14</day><month>10</month><year>2005</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2006</year></date></history><copyright-statement>Copyright &#x000a9; 2006 Gunel-Ozcan et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>The hereditary hemochromatosis gene <italic>HFE </italic>plays a pivotal role in iron homeostasis. The association between cancer and HFE hetero- or homozygosity has previously been shown including hepatocellular and nonhepatocellular malignancies. This study was performed to compare frequencies of <italic>HFE </italic>C282Y and H63D variants in Turkish women with breast cancer and healthy controls.</p></sec><sec sec-type="methods"><title>Methods</title><p>Archived DNA samples of Hacettepe University Oncology Institute were used in this study. The <italic>HFE </italic>gene was investigated by PCR-RFLP.</p></sec><sec><title>Results</title><p>All subjects studied were free from C282Y mutation. Thirty-nine patients had H63D mutation and were all heterozygous. H63D allele frequency was 22.2% (39/176) in the breast cancer patients, and 14% (28/200) in the healthy volunteers. Statistical analysis of cases with <italic>HFE </italic>H63D phenotype showed significant difference between breast cancer and healthy volunteers (<italic>P </italic>= 0.02).</p></sec><sec><title>Conclusion</title><p>Our results suggest that <italic>HFE </italic>H63D mutation frequencies were increased in the breast cancer patients in comparison to those in the general population. Also, odds ratios (odds ratio = 2.05) computed in this study suggest that H63D has a positive association with breast cancer.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The hereditary hemochromatosis gene <italic>HFE </italic>(6p21.3) 4 Mb telomeric to the <italic>HLA-A </italic>locus, and its product has a structure similar to MHC class I molecules [<xref ref-type="bibr" rid="B1">1</xref>]. It has a critical role in iron homeostasis. The total number of <italic>HFE </italic>variants detected to date is at least 37, of which 19 are missense [<xref ref-type="bibr" rid="B2">2</xref>]. Two mutations, C282Y (the substitution of tyrosine for cysteine at position 282) and H63D (the substitution of aspartate for histidine at position 63), are particularly frequent among patients with hereditary hemochromatosis [<xref ref-type="bibr" rid="B1">1</xref>] that is characterized by hepatic fibrosis and cirrhosis, diabetes mellitus, skin pigmentation, hypogonadism, arthropathy and cardiomyopathy as a result of excessive iron absorption from the gut and subsequent accumulation of iron in organs. HFE protein forms a stable complex with transferrin receptor (TFR), thereby reducing its affinity for transferrin (TF) by approximately ten fold [<xref ref-type="bibr" rid="B3">3</xref>]. TF is the major iron transport protein in blood and TFR facilitates the uptake of ironbound transferrin. C282Y mutation prevents the association of the mutant HFE protein with TFR because of the lack of cell surface expression [<xref ref-type="bibr" rid="B4">4</xref>]. As a result, increased affinity of the uncomplexed TFR for TF causes higher iron absorption. The significance of the H63D mutation on the <italic>HFE </italic>gene was at first controversial [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Subsequent studies suggested a functional role for H63D mutation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The H63D variant of the HFE protein does reach the cell surface and forms a stable complex with TFR but fails to control high TFR affinity for TF [<xref ref-type="bibr" rid="B7">7</xref>].</p><p><italic>HFE </italic>mutation frequencies show marked geographical differences throughout the world. Most Caucasian patients of Northwestern European ancestry with hereditary hemochromatosis are homozygous for C282Y [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Compound heterozygotes for the C282Y and H63D mutations expressing hemochromatosis are also observed, but with less penetrance than C282Y homozygotes [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Besides hepatocellular carcinoma [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] common malignancies, including hematological [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>], colorectal cancer [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>], and breast cancer [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B18">18</xref>] show risk associations with C282Y. However, there are contradictious studies showing no association between the <italic>HFE </italic>mutations and cancer risk [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>].</p><p>One possible mechanism for the association might be the load of reactive free iron molecules which may cause DNA damage [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], which may suppress the host defense cells and induce proliferation [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>], and which may convert nitric oxide from a proapoptotic to an antiapoptotic molecule [<xref ref-type="bibr" rid="B27">27</xref>].</p><p>The current report outlines our analysis of C282Y and H63D mutations in Turkish breast cancer patients and control subjects from the same geographical area.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and Controls</title><p>In this study, we used 88 archived DNA samples, which had been isolated from blood samples of patients with breast cancer diagnosed at Hacettepe University Oncology Institute Department of Medical Oncology in Turkey over the last ten years. The mean age at diagnosis for the breast cancer patients was 41 yr (range, 21&#x02013;75). The population controls consisted of 100 DNA samples from voluntary and healthy women who lived in Ankara, located at central Turkey. The mean age of the controls was 33 yr (range, 21&#x02013;70). This study has been approved by the Hacettepe University Ethics Committee.</p></sec><sec><title>PCR-RFLP</title><p>PCR amplification and electrophoresis were performed by using the standard procedures described previously [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. The following general HFE primers were used at annealing temperature of 58&#x000b0;C and 57.4&#x000b0;C for analysis of C282Y and H63D mutations:</p><p>C282Y-Forward; 5'-TGGCAAGGGTAAACAGATCC-3',</p><p>C282Y-Reverse; 5'-CTCAGGCACTCCTCTCAACC-3',</p><p>H63D-Forward; 5'-ACATGGTTAAGGCCTGTTGC-3',</p><p>H63D-Reverse; 5'-GCCACATCTGGCTTGAAATT-3'.</p><p>The amplified fragments were digested with <italic>Rsa</italic>I for the C282Y and <italic>Bcl</italic>I for the H63D mutations. Upon digestion with <italic>Rsa</italic>I, the 387 bp PCR product of C282Y region shows two fragments of 247 bp and 140 bp in normal DNA and two additional fragments of 111 bp and 29 bp in mutant DNA. The 294 bp H63D region PCR product digested with <italic>Bcl</italic>I generates fragments of 138 bp, 70 bp in normal DNA and 208 bp in mutant DNA [<xref ref-type="bibr" rid="B28">28</xref>]. PCR digests were analyzed on 2.5% agarose gels (Figure <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>). The relative positions of the mutations analyzed in the present study are given in Table <xref ref-type="table" rid="T1">1</xref>.</p></sec><sec><title>Statistical analyses</title><p>Frequencies of the <italic>HFE </italic>alleles were calculated by gene counting. Hardy-Weinberg equilibrium was tested before proceeding to the analysis. Statistical analysis of mutation prevalence in case and control groups was performed by using two-tailed Fisher's exact test. The proportions of patients with breast cancer and healthy volunteers who carried at least one mutant allele are presented with 95% confidence intervals (CIs) and Odds Ratio (OR). Analyses were performed by using Instat V2.02 (GraphPad Inc USA) statistical software package. In general group comparisons <italic>P </italic>value &#x0003c; 0.05 was accepted as statistically significant whereas in subgroup analysis after making Bonferroni adjustment <italic>P </italic>value &#x0003c; 0.0125 value was accepted as statistically significant.</p></sec></sec><sec><title>Results</title><p>According to the birth of place thirty-eight percent of the entire cases was from Central Turkey, twenty-eight percent was from South and West (Mediterranean region), twenty percent was from East, and fifteen percent was from North (Black Sea region). Information about cancer type and stages were available for 52 patients, and ninety-three percent of them had infiltrative ductal carcinoma and ninety-four percent of the women had limited-stage (stages I-III), 3 women (6%) had distant metastases at diagnosis.</p><p>There was no significant deviation from Hardy-Weinberg equilibrium in the distribution of genotypes in the control group. In the control group of 100 women, <italic>HFE </italic>H63D allele frequency was 14%, and the frequency of <italic>HFE </italic>H63D-homozygosity was 1%. Overall allele frequency for breast cancer group of 88 women (71 sporadic and 17 familial), for <italic>HFE </italic>H63D was 22.2% whereas there were no <italic>HFE </italic>H63D-homozygotes in the group. Statistical analysis of cases with <italic>HFE </italic>H63D phenotype showed significant difference between breast cancer and healthy volunteers (<italic>P </italic>= 0.02, OR = 2.05, 95% CI = 1.12 to 3.75) whereas there was no significant difference between either familial breast cancer and healthy volunteers or familial and sporadic breast cancer groups (Table <xref ref-type="table" rid="T3">3</xref>). Subgroup analysis showed that the difference between the cases and control groups is based on the sporadic cases (P = 0.0001, OR = 3.13, 95% CI = 1.65 to 5.94). Information for the pre- and post-menopausal status was available for only 64 patients. Statistical analysis of cases with <italic>HFE </italic>H63D mutation among these patients showed no significant differences between premenopasual and postmenopausal breast cancer (Table <xref ref-type="table" rid="T3">3</xref>). Characteristics of breast cancer patients with respect to <italic>H63D </italic>allele are summarized in Table <xref ref-type="table" rid="T2">2</xref>. There were also no statistically significant differences between breast cancer patients with and without the H63D allele with respect to age or heredity. All subjects studied were free from C282Y mutation.</p></sec><sec><title>Discussion</title><p>As expected from previous population studies [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>] we did not find any C282Y mutation among the Turkish women who participated in this study. The results of this case-control study showed that H63D was more common in breast cancer patients. Because endogenous estrogens are more closely related to postmenopausal breast cancer and iron might have a role at redox-cycling estrogen metabolites to produce hydroxyl radicals [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>], we compared premenopasual and postmenopausal breast cancer for the <italic>HFE </italic>H63D mutation. Since significant iron loss stops with menopause, an increase in <italic>HFE</italic>-associated cancer risk might also be possible. Contrary, there was no statistically significant difference between these groups (<italic>P </italic>= 0.12).</p><p>To the best of our knowledge, this is the second study that shows a significant association between female breast cancer and <italic>HFE</italic>-H63D although a subgroup analysis in a general cancer association study also revealed a non-significantly increased odds ratio for H63D carriers (n = 18, OR = 2.0, <italic>P </italic>= 0.14) in breast cancer [<xref ref-type="bibr" rid="B12">12</xref>]. A recent article, making the same comparisons of H63D mutation frequency between Russian women with breast cancer and controls, found age to be an important confounder of the association, wherein a positive association of H63D with breast cancer was only found among women over 57 years old [<xref ref-type="bibr" rid="B34">34</xref>]. Because of the insufficient number of the women over 45 years old in our study (Control N = 5, Cases N = 22), the estimation could be made in wide range which might cause unreliable interpretations. Therefore, age-specific analysis was not performed in this study. Another recent study showed no association between male breast cancer and H63D [<xref ref-type="bibr" rid="B35">35</xref>]. Although the lack of gender difference shown in association between <italic>HFE </italic>genotypes and medical conditions related to iron overload other than cancer [<xref ref-type="bibr" rid="B36">36</xref>], this variability in women with H63D mutations with respect to cancer risk could be the influence of potential modifier factors for breast cancer. The only other cancer association with H63D is with malignant gliomas [<xref ref-type="bibr" rid="B37">37</xref>]. If replicated elsewhere, further studies can be designed to distinguish between mechanistic possibilities. Our study had some limitations. We were unable to study the effect of H63D on serum iron parameters or gene and environment interactions, as we did not have stored serum samples from patients nor dietary or medication (oral contraceptives, etc) history. Ideally, a sample larger than ours should be studied in a genetic association study to rule out the chance factor. Not only is the study small, but when a small number of multiple comparisons are made, the power of the study is further diminished. When Bonferroni correction were made the comparison between the cases and controls in this study was no longer significant (<italic>p </italic>= 0.02 vs. <italic>a </italic>= 0.0125).</p><p>We compared the data on H63D frequencies from other population studies in Turkey. Our control frequency from age-matched females is in general agreement with other results which are 13.6%, 11.6% respectively [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. The only exception is the study by Simsek et al., which reported a higher H63D mutation frequency (24.9%) from predominantly male blood donors [<xref ref-type="bibr" rid="B31">31</xref>]. A larger control group consisting of truly population-based females would have yielded a more robust estimate of the frequency if we had had the resources to achieve that.</p><p>The role of H63D in iron homeostasis is well established. Although an animal study unambiguously showed an effect of H63D mutation on hemochromatosis development [<xref ref-type="bibr" rid="B38">38</xref>], a human twin study established the influence of H63D on transferrin saturation levels [<xref ref-type="bibr" rid="B39">39</xref>]. Significant increases in both transferrin saturation and serum ferritin levels in H63D heterozygotes versus HFE wild type controls have also been demonstrated in large population studies [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. <italic>HFE </italic>H63D mutation is very variable worldwide. The carrier frequency of the H63D mutation is 21.6% in Europe, 5.4% in Africa/Middle-East, 2.8% Asia and 22.8% in America [<xref ref-type="bibr" rid="B9">9</xref>]. One possibility is that H63D association with breast cancer might have been a selection of a specific subgroup among Turkish population. Turkey has a very heterogeneous population whose ancestries are from Anatolia (east Mediterranean region), Middle East and Central Asia. Related or unrelated susceptibility gene mutations, especially the ones which show ethnic dependence may both arise at higher frequencies in a specific subgroup of the mix-population. However, being a reference center Hacettepe Oncology Institute has the potential to comprise patients from different regions of Turkey and therefore, it is less likely that a specific subgroup of the population has been selected for this study.</p><p>Despite a large physical distance, the genetic distance between <italic>HFE </italic>and the telomeric end of the <italic>HLA </italic>complex is less than 1 cM. This results in linkage disequilibrium between H63D and <italic>HLA</italic>-A29 [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. One alternative explanation is therefore confounding by locus, e.g., an <italic>HLA </italic>association may have appeared as H63D association in our study due to linkage disequilibrium. <italic>HLA </italic>loci have been studied in breast cancer and several associations have been reported but most importantly a recent large family study mapped a breast cancer susceptibility locus towards the telomeric end of the <italic>HLA </italic>complex [<xref ref-type="bibr" rid="B45">45</xref>]. The region between <italic>HFE </italic>and the <italic>HLA </italic>complex has another feature that may be relevant in the mechanism of an association with H63D. A significant correlation with CD8<sup>+ </sup>T-cell numbers, but not with CD4<sup>+ </sup>T-cell numbers, in subjects carrying both <italic>HLA</italic>-A29 and H63D or both <italic>HLA</italic>-A*01 and H63D mutation has been reported [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B46">46</xref>]. Thus, the H63D association may be a reflection of an immune response gene association in the region between <italic>HFE </italic>and <italic>HLA</italic>. Further large studies on <italic>HFE </italic>association with breast cancer susceptibility in populations lacking the C282Y mutation may need to include markers from <italic>HLA </italic>loci, loci between the <italic>HLA </italic>complex and <italic>HFE </italic>and other variants of the <italic>HFE </italic>gene for more meaningful results than our preliminary study has shown.</p></sec><sec><title>Conclusion</title><p>We did not find any C282Y mutation among the Turkish women who participated in this study. The results of this case-control study show that H63D has a positive association with breast cancer. However, when a small number of multiple comparisons are made, the power of the study is diminished. Ideally, a sample larger than ours should be studied in a genetic association study to rule out the chance factor.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AGO designed the study, carried out the molecular genetic (PCR-RFLP) studies, performed the statistical analysis and drafted the manuscript. SAB participated in the PCR-RFLP studies. ENG is the medical oncologist who diagnosed breast cancer patients and gave the related information. DG provided DNA samples of the patients and control group and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/37/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported in part by Kirikkale University Research Found (K&#x000dc; AF 02/08.01.04) and Eczacibasi Scientific Research and Award Found. We thank the cancer patients and healthy volunteers who made this analysis possible. We also thank Professor M. Oguz Guc and Handan Camdeviren-Ankarali for reviewing the statistical analysis.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Gnirke</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>W</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Ruddy</surname><given-names>DA</given-names></name><name><surname>Basava</surname><given-names>A</given-names></name><name><surname>Dormishian</surname><given-names>F</given-names></name><name><surname>Domingo</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Ellis</surname><given-names>MC</given-names></name><name><surname>Fullan</surname><given-names>A</given-names></name><name><surname>Hinton</surname><given-names>LM</given-names></name><name><surname>Jones</surname><given-names>NL</given-names></name><name><surname>Kimmel</surname><given-names>BE</given-names></name><name><surname>Kronmal</surname><given-names>GS</given-names></name><name><surname>Lauer</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>VK</given-names></name><name><surname>Loeb</surname><given-names>DB</given-names></name><name><surname>Mapa</surname><given-names>FA</given-names></name><name><surname>McClelland</surname><given-names>E</given-names></name><name><surname>Meyer</surname><given-names>NC</given-names></name><name><surname>Mintier</surname><given-names>GA</given-names></name><name><surname>Moeller</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>T</given-names></name><name><surname>Morikang</surname><given-names>E</given-names></name><name><surname>Prass</surname><given-names>CE</given-names></name><name><surname>Quintana</surname><given-names>L</given-names></name><name><surname>Starnes</surname><given-names>SM</given-names></name><name><surname>Schatzman</surname><given-names>RC</given-names></name><name><surname>Brunke</surname><given-names>KJ</given-names></name><name><surname>Drayna</surname><given-names>DT</given-names></name><name><surname>Risch</surname><given-names>NJ</given-names></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Wolff</surname><given-names>RK</given-names></name></person-group><article-title>A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">8696333</pub-id><pub-id pub-id-type="doi">10.1038/ng0896-399</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>L</given-names></name><name><surname>Beutler</surname><given-names>E</given-names></name></person-group><article-title>Hematologically important mutations: iron storage diseases</article-title><source>Blood Cells Mol Dis</source><year>2004</year><volume>33</volume><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15223009</pub-id><pub-id pub-id-type="doi">10.1016/j.bcmd.2004.03.002</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Penny</surname><given-names>DM</given-names></name><name><surname>Irrinki</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>VK</given-names></name><name><surname>Lebron</surname><given-names>JA</given-names></name><name><surname>Watson</surname><given-names>N</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Sigal</surname><given-names>E</given-names></name><name><surname>Bjorkman</surname><given-names>PJ</given-names></name><name><surname>Schatzman</surname><given-names>RC</given-names></name></person-group><article-title>The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>1472</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">9465039</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.4.1472</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Irrinki</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>VK</given-names></name><name><surname>Mapa</surname><given-names>FA</given-names></name><name><surname>Morikang</surname><given-names>E</given-names></name><name><surname>Prass</surname><given-names>CE</given-names></name><name><surname>Starnes</surname><given-names>SM</given-names></name><name><surname>Wolff</surname><given-names>RK</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name><name><surname>Schatzman</surname><given-names>RC</given-names></name></person-group><article-title>The hemochromatosis founder mutation in HLA-H disrupts b<sub>2</sub>-microglobulin interaction and cell surface expression</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>14025</fpage><lpage>14028</lpage><pub-id pub-id-type="pmid">9162021</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.22.14025</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E</given-names></name></person-group><article-title>The significance of the 187G (H63D) mutation in hemochromatosis</article-title><source>Am J Hum Genet</source><year>1997</year><volume>61</volume><fpage>762</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">9326341</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairbanks</surname><given-names>VF</given-names></name><name><surname>Brandhagen</surname><given-names>DJ</given-names></name><name><surname>Thibodeau</surname><given-names>SN</given-names></name><name><surname>Snow</surname><given-names>K</given-names></name><name><surname>Wollan</surname><given-names>PC</given-names></name></person-group><article-title>H63D is an haemochromatosis associated allele</article-title><source>Gut</source><year>1998</year><volume>43</volume><fpage>441</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">9863493</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>XY</given-names></name><name><surname>Tomatsu</surname><given-names>S</given-names></name><name><surname>Tsuchihashi</surname><given-names>Z</given-names></name><name><surname>Feder</surname><given-names>JN</given-names></name><name><surname>Schatzman</surname><given-names>RC</given-names></name><name><surname>Britton</surname><given-names>RS</given-names></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>12384</fpage><lpage>12389</lpage><pub-id pub-id-type="pmid">9356458</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.23.12384</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E</given-names></name><name><surname>Gelbart</surname><given-names>T</given-names></name><name><surname>West</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Blackstone</surname><given-names>R</given-names></name><name><surname>Pockros</surname><given-names>P</given-names></name><name><surname>Kosty</surname><given-names>M</given-names></name><name><surname>Venditti</surname><given-names>CP</given-names></name><name><surname>Phatak</surname><given-names>PD</given-names></name><name><surname>Seese</surname><given-names>NK</given-names></name><name><surname>Chorney</surname><given-names>KA</given-names></name><name><surname>Ten Elshof</surname><given-names>AE</given-names></name><name><surname>Gerhard</surname><given-names>GS</given-names></name><name><surname>Chorney</surname><given-names>M</given-names></name></person-group><article-title>Mutation analysis in hereditary hemochromatosis</article-title><source>Blood Cells Mol Dis</source><year>1996</year><volume>22</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">8931958</pub-id><pub-id pub-id-type="doi">10.1006/bcmd.1996.0027</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>EH</given-names></name><name><surname>Imperatore</surname><given-names>G</given-names></name><name><surname>Burke</surname><given-names>W</given-names></name></person-group><article-title>HFE gene and Hereditary Hemochromatosis: a HuGE review. Human Genome Epidemiology</article-title><source>Am J Epidemiol</source><year>2001</year><volume>154</volume><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">11479183</pub-id><pub-id pub-id-type="doi">10.1093/aje/154.3.193</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>Poppl</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Scholmerich</surname><given-names>J</given-names></name><name><surname>Lock</surname><given-names>G</given-names></name></person-group><article-title>HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence</article-title><source>Clin Gastroenterol Hepatol</source><year>2003</year><volume>1</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">15017669</pub-id><pub-id pub-id-type="doi">10.1016/S1542-3565(03)00132-0</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cauza</surname><given-names>E</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M</given-names></name><name><surname>Ulrich-Pur</surname><given-names>H</given-names></name><name><surname>Datz</surname><given-names>C</given-names></name><name><surname>Gschwantler</surname><given-names>M</given-names></name><name><surname>Schoniger-Hekele</surname><given-names>M</given-names></name><name><surname>Hackl</surname><given-names>F</given-names></name><name><surname>Polli</surname><given-names>C</given-names></name><name><surname>Rasoul-Rockenschaub</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Wrba</surname><given-names>F</given-names></name><name><surname>Gangl</surname><given-names>A</given-names></name><name><surname>Ferenci</surname><given-names>P</given-names></name></person-group><article-title>Mutations of the HFE gene in patients with hepatocellular carcinoma</article-title><source>Am J Gastroenterol</source><year>2003</year><volume>98</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">12591066</pub-id><pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07222.x</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>JC</given-names></name><name><surname>Bertoli</surname><given-names>LF</given-names></name><name><surname>Acton</surname><given-names>RT</given-names></name></person-group><article-title>HFE C282Y and H63D in adults with malignancies in a community medical oncology practice</article-title><source>BMC Cancer</source><year>2004</year><volume>4</volume><fpage>6</fpage><pub-id pub-id-type="pmid">15018631</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-4-6</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorak</surname><given-names>MT</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Worwood</surname><given-names>M</given-names></name><name><surname>Sproul</surname><given-names>AM</given-names></name><name><surname>Gibson</surname><given-names>BE</given-names></name></person-group><article-title>The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>3957</fpage><lpage>3958</lpage><pub-id pub-id-type="pmid">10627122</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorak</surname><given-names>MT</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Worwood</surname><given-names>M</given-names></name></person-group><article-title>HFE gene mutations in susceptibility to childhood leukemia: HuGE review</article-title><source>Genet Med</source><year>2005</year><volume>7</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">15775751</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beckman</surname><given-names>LE</given-names></name><name><surname>Van Landeghem</surname><given-names>GF</given-names></name><name><surname>Sikstr&#x000f6;m</surname><given-names>C</given-names></name><name><surname>Wahlin</surname><given-names>A</given-names></name><name><surname>Markevarn</surname><given-names>B</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Lenner</surname><given-names>P</given-names></name><name><surname>Athlin</surname><given-names>L</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Beckman</surname><given-names>L</given-names></name></person-group><article-title>Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders</article-title><source>Carcinogenesis</source><year>1999</year><volume>20</volume><fpage>1231</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">10383894</pub-id><pub-id pub-id-type="doi">10.1093/carcin/20.7.1231</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altes</surname><given-names>A</given-names></name><name><surname>Gimferrer</surname><given-names>E</given-names></name><name><surname>Capella</surname><given-names>G</given-names></name><name><surname>Barcelo</surname><given-names>MJ</given-names></name><name><surname>Baiget</surname><given-names>M</given-names></name></person-group><article-title>Colorectal cancer and HFE gene mutations</article-title><source>Haematologica</source><year>1999</year><volume>84</volume><fpage>479</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">10329938</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>JP</given-names></name><name><surname>Johnson</surname><given-names>VL</given-names></name><name><surname>Rogers</surname><given-names>PA</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name><name><surname>Thomas</surname><given-names>HJ</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Silver</surname><given-names>AR</given-names></name></person-group><article-title>Evidence for association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk colorectal cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2005</year><volume>14</volume><fpage>1460</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">15941956</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-04-0672</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kallianpur</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>LD</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Christman</surname><given-names>BW</given-names></name><name><surname>Dittus</surname><given-names>RS</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Parl</surname><given-names>FF</given-names></name><name><surname>Summar</surname><given-names>ML</given-names></name></person-group><article-title>Increased Prevalence of the HFE C282Y Hemochromatosis Allele in Women with Breast Cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2004</year><volume>13</volume><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">14973098</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-03-0188</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannuksela</surname><given-names>J</given-names></name><name><surname>Savolainen</surname><given-names>ER</given-names></name><name><surname>Koistinen</surname><given-names>P</given-names></name><name><surname>Parkkila</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders</article-title><source>Haematologica</source><year>2002</year><volume>87</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">11836162</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der</surname><given-names>ADL</given-names></name><name><surname>van der Hel</surname><given-names>O</given-names></name><name><surname>Roest</surname><given-names>M</given-names></name><name><surname>van der Shouw</surname><given-names>YT</given-names></name><name><surname>van Gils</surname><given-names>CH</given-names></name><name><surname>Marx</surname><given-names>JJ</given-names></name><name><surname>van Noord</surname><given-names>PA</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name></person-group><article-title>Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands)</article-title><source>Cancer Causes Control</source><year>2003</year><volume>14</volume><fpage>541</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">12948285</pub-id><pub-id pub-id-type="doi">10.1023/A:1024839528684</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorak</surname><given-names>MT</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Worwood</surname><given-names>M</given-names></name></person-group><article-title>Hemochromatosis gene in leukemia and lymphoma</article-title><source>Leuk Lymphoma</source><year>2002</year><volume>43</volume><fpage>467</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">12002748</pub-id><pub-id pub-id-type="doi">10.1080/10428190290011930</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>BK</given-names></name><name><surname>Justenhoven</surname><given-names>C</given-names></name><name><surname>Pesch</surname><given-names>B</given-names></name><name><surname>Harth</surname><given-names>V</given-names></name><name><surname>Weirich</surname><given-names>G</given-names></name><name><surname>Baisch</surname><given-names>C</given-names></name><name><surname>Rabstein</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>YD</given-names></name><name><surname>Bruning</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>HP</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Brod</surname><given-names>S</given-names></name><name><surname>Oberkanins</surname><given-names>C</given-names></name><name><surname>Hamann</surname><given-names>U</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><collab>GENICA Network</collab></person-group><article-title>Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2005</year><volume>14</volume><fpage>1102</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">15894659</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0013</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nunoshiba</surname><given-names>T</given-names></name><name><surname>Obata</surname><given-names>F</given-names></name><name><surname>Boss</surname><given-names>AC</given-names></name><name><surname>Oikawa</surname><given-names>S</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Kawanishi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group><article-title>Role of iron and superoxide for generation of hydroxyl radical, oxidative DNA lesions, and mutagenesis in Escherichia coli</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>34832</fpage><lpage>34837</lpage><pub-id pub-id-type="pmid">10574955</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.49.34832</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>B</given-names></name></person-group><article-title>Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation</article-title><source>Nutrition</source><year>1995</year><volume>11</volume><fpage>646</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">8748242</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Sousa</surname><given-names>M</given-names></name></person-group><article-title>Immune cell functions in iron overload</article-title><source>Clin Exp Immunol</source><year>1989</year><volume>75</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2649280</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Esparza</surname><given-names>I</given-names></name><name><surname>Schreiber</surname><given-names>R</given-names></name></person-group><article-title>Iron inhibits the non-specific tumoricidal activity of macrophages: a possible contributory mechanism for neoplasia in hemochromatosis</article-title><source>Ann N Y Acad Sci</source><year>1988</year><volume>526</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">2455463</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>RJ</given-names></name><name><surname>Streiff</surname><given-names>RR</given-names></name><name><surname>Elliot</surname><given-names>GT</given-names></name></person-group><article-title>Influence of iron on in vivo proliferation and lethality of L 1210 cells</article-title><source>J Nutr</source><year>1985</year><volume>115</volume><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">3973748</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koeken</surname><given-names>A</given-names></name><name><surname>Cobbaert</surname><given-names>C</given-names></name><name><surname>Quint</surname><given-names>W</given-names></name><name><surname>van Doorn</surname><given-names>LJ</given-names></name></person-group><article-title>Genotyping of hemochromatosis-associated mutations in the HFE gene by PCR-RFLP and a novel reverse hybridization method</article-title><source>Clin Chem Lab Med</source><year>2002</year><volume>40</volume><fpage>122</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">11939483</pub-id><pub-id pub-id-type="doi">10.1515/CCLM.2002.021</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merryweather-Clarke</surname><given-names>AT</given-names></name><name><surname>Pointon</surname><given-names>JJ</given-names></name><name><surname>Shearman</surname><given-names>JD</given-names></name><name><surname>Robson</surname><given-names>KJ</given-names></name></person-group><article-title>Global prevalence of putative haemochromatosis mutations</article-title><source>J Med Genet</source><year>1997</year><volume>34</volume><fpage>275</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">9138148</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bozkaya</surname><given-names>H</given-names></name><name><surname>Bektas</surname><given-names>M</given-names></name><name><surname>Metin</surname><given-names>O</given-names></name><name><surname>Erkan</surname><given-names>O</given-names></name><name><surname>Ibrahimoglu</surname><given-names>D</given-names></name><name><surname>Dalva</surname><given-names>K</given-names></name><name><surname>Akbiyik</surname><given-names>F</given-names></name><name><surname>Gurel</surname><given-names>S</given-names></name><name><surname>Bozdayi</surname><given-names>AM</given-names></name><name><surname>Akay</surname><given-names>C</given-names></name><name><surname>Yurdaydin</surname><given-names>C</given-names></name><name><surname>Aslan</surname><given-names>O</given-names></name><name><surname>Uzunalimoglu</surname><given-names>O</given-names></name></person-group><article-title>Screening for hemochromatosis in Turkey</article-title><source>Dig Dis Sci</source><year>2004</year><volume>49</volume><fpage>444</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">15139495</pub-id><pub-id pub-id-type="doi">10.1023/B:DDAS.0000020500.26184.ce</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simsek</surname><given-names>H</given-names></name><name><surname>Sumer</surname><given-names>H</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Balaban</surname><given-names>YH</given-names></name><name><surname>Ozcebe</surname><given-names>O</given-names></name><name><surname>Hascelik</surname><given-names>G</given-names></name><name><surname>Buyukask</surname><given-names>Y</given-names></name><name><surname>Tatar</surname><given-names>G</given-names></name></person-group><article-title>Frequency of HFE mutations among Turkish blood donors according to transferrin saturation: genotype screening for hereditary hemochromatosis among voluntary blood donors in Turkey</article-title><source>J Clin Gastroenterol</source><year>2004</year><volume>38</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">15319650</pub-id><pub-id pub-id-type="doi">10.1097/01.mcg.0000135901.52818.f7</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liehr</surname><given-names>JG</given-names></name><name><surname>Jones</surname><given-names>JS.</given-names></name></person-group><article-title>Role of iron in estrogen-induced cancer</article-title><source>Curr Med Chem</source><year>2001</year><volume>8</volume><fpage>839</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">11375754</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malins</surname><given-names>DC</given-names></name><name><surname>Polissar</surname><given-names>NL</given-names></name><name><surname>Gunselman</surname><given-names>SJ</given-names></name></person-group><article-title>Progression of human breast cancer to the metastatic state is linked to hydroxyl radical-induced DNA damage</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>2557</fpage><lpage>2563</lpage><pub-id pub-id-type="pmid">8637913</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.6.2557</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondrashova</surname><given-names>TV</given-names></name><name><surname>Neriishi</surname><given-names>K</given-names></name><name><surname>Ban</surname><given-names>S</given-names></name><name><surname>Ivanova</surname><given-names>TI</given-names></name><name><surname>Krikunova</surname><given-names>LI</given-names></name><name><surname>Shentereva</surname><given-names>NI</given-names></name><name><surname>Smirnova</surname><given-names>IA</given-names></name><name><surname>Zharikova</surname><given-names>IA</given-names></name><name><surname>Konova</surname><given-names>MV</given-names></name><name><surname>Taira</surname><given-names>S</given-names></name><name><surname>Tsyb</surname><given-names>AF</given-names></name></person-group><article-title>Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers</article-title><source>Biochim Biophys Acta</source><year>2005</year><volume>1762</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16216474</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Syrjakoski</surname><given-names>KFH</given-names></name><name><surname>Ikonen</surname><given-names>T</given-names></name><name><surname>Kuukasjarvi</surname><given-names>T</given-names></name><name><surname>Autio</surname><given-names>V</given-names></name><name><surname>Matikainen</surname><given-names>MP</given-names></name><name><surname>Tammela</surname><given-names>TLJ</given-names></name><name><surname>Koivisto</surname><given-names>PA</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name></person-group><article-title>Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><fpage>518</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">16003728</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21331</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PC</given-names></name><name><surname>Reboussin</surname><given-names>DM</given-names></name><name><surname>Barton</surname><given-names>JC</given-names></name><name><surname>McLaren</surname><given-names>CE</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><name><surname>McLaren</surname><given-names>GD</given-names></name><name><surname>Dawkins</surname><given-names>FW</given-names></name><name><surname>Acton</surname><given-names>RT</given-names></name><name><surname>Harris</surname><given-names>EL</given-names></name><name><surname>Gordeuk</surname><given-names>VR</given-names></name><name><surname>Leiendecker-Foster</surname><given-names>C</given-names></name><name><surname>Speechley</surname><given-names>M</given-names></name><name><surname>Snively</surname><given-names>BM</given-names></name><name><surname>Holup</surname><given-names>JL</given-names></name><name><surname>Thomson</surname><given-names>E</given-names></name><name><surname>Sholinsky</surname><given-names>P</given-names></name></person-group><article-title>Hemochromatosis and iron-overload screening in a racially diverse population</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1769</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">15858186</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa041534</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez di Montemuros</surname><given-names>F</given-names></name><name><surname>Tavazzi</surname><given-names>D</given-names></name><name><surname>Salsano</surname><given-names>E</given-names></name><name><surname>Piepoli</surname><given-names>T</given-names></name><name><surname>Pollo</surname><given-names>B</given-names></name><name><surname>Fiorelli</surname><given-names>G</given-names></name><name><surname>Finocchiaro</surname><given-names>G</given-names></name></person-group><article-title>High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>1342</fpage><pub-id pub-id-type="pmid">11591868</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomatsu</surname><given-names>S</given-names></name><name><surname>Orii</surname><given-names>KO</given-names></name><name><surname>Fleming</surname><given-names>RE</given-names></name><name><surname>Holden</surname><given-names>CC</given-names></name><name><surname>Waheed</surname><given-names>A</given-names></name><name><surname>Britton</surname><given-names>RS</given-names></name><name><surname>Gutierrez</surname><given-names>MA</given-names></name><name><surname>Velez-Castrillon</surname><given-names>S</given-names></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Sly</surname><given-names>WS</given-names></name></person-group><article-title>Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>15788</fpage><lpage>15793</lpage><pub-id pub-id-type="pmid">14673107</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2237037100</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitfield</surname><given-names>JB</given-names></name><name><surname>Cullen</surname><given-names>LM</given-names></name><name><surname>Jazwinska</surname><given-names>EC</given-names></name><name><surname>Powell</surname><given-names>LW</given-names></name><name><surname>Heath</surname><given-names>AC</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Duffy</surname><given-names>DL</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name></person-group><article-title>Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins</article-title><source>Am J Hum Genet</source><year>2000</year><volume>66</volume><fpage>1246</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">10739755</pub-id><pub-id pub-id-type="doi">10.1086/302862</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>E</given-names></name><name><surname>Felitti</surname><given-names>VJ</given-names></name><name><surname>Koziol</surname><given-names>JA</given-names></name><name><surname>Ho</surname><given-names>NJ</given-names></name><name><surname>Gelbart</surname><given-names>T</given-names></name></person-group><article-title>Penetrance of 845G--&#x0003e; A (C282Y) HFE hereditary haemochromatosis mutation in the USA</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">11812557</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(02)07447-0</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>K</given-names></name><name><surname>Darke</surname><given-names>C</given-names></name><name><surname>Guttridge</surname><given-names>MG</given-names></name><name><surname>Ravine</surname><given-names>D</given-names></name><name><surname>Hutton</surname><given-names>RD</given-names></name><name><surname>Napier</surname><given-names>JA</given-names></name><name><surname>Worwood</surname><given-names>M</given-names></name></person-group><article-title>HFE mutations, iron deficiency and overload in 10,500 blood donors</article-title><source>Br J Haematol</source><year>2001</year><volume>114</volume><fpage>474</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">11529872</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2141.2001.02949.x</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>W</given-names></name><name><surname>Imperatore</surname><given-names>G</given-names></name><name><surname>McDonnell</surname><given-names>SM</given-names></name><name><surname>Baron</surname><given-names>RC</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name></person-group><article-title>Contribution of different HFE genotypes to iron overload disease: a pooled analysis</article-title><source>Genet Med</source><year>2000</year><volume>2</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">11399207</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>G</given-names></name><name><surname>Alves</surname><given-names>H</given-names></name><name><surname>Rodrigues</surname><given-names>P</given-names></name><name><surname>Cabeda</surname><given-names>JM</given-names></name><name><surname>Portal</surname><given-names>C</given-names></name><name><surname>Ruivo</surname><given-names>A</given-names></name><name><surname>Justica</surname><given-names>B</given-names></name><name><surname>Wolff</surname><given-names>R</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name></person-group><article-title>Major histocompatibility complex class I associations in iron overload: evidence for a new link between the HFE H63D mutation, HLA-A29, and non-classical forms of hemochromatosis</article-title><source>Immunogenetics</source><year>1998</year><volume>47</volume><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9510559</pub-id><pub-id pub-id-type="doi">10.1007/s002510050376</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>CS</given-names></name><name><surname>Alves</surname><given-names>H</given-names></name><name><surname>Mascarenhas</surname><given-names>M</given-names></name><name><surname>Goncalves</surname><given-names>R</given-names></name><name><surname>Oliveira</surname><given-names>P</given-names></name><name><surname>Rodrigues</surname><given-names>P</given-names></name><name><surname>Cruz</surname><given-names>E</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name><name><surname>Porto</surname><given-names>G</given-names></name></person-group><article-title>Co-selection of the H63D mutation and the HLA-29 allele: a new paradigm of linkage disequilibrium?</article-title><source>Immunogenetics</source><year>2002</year><volume>53</volume><fpage>1002</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">11904676</pub-id><pub-id pub-id-type="doi">10.1007/s00251-001-0414-8</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>M</given-names></name><name><surname>Nolte</surname><given-names>IM</given-names></name><name><surname>de Vries</surname><given-names>EGE</given-names></name><name><surname>Schaapveld</surname><given-names>M</given-names></name><name><surname>Kleibeuker</surname><given-names>JH</given-names></name><name><surname>Oosterom</surname><given-names>E</given-names></name><name><surname>Oosterwijk</surname><given-names>JC</given-names></name><name><surname>van der Hout</surname><given-names>AH</given-names></name><name><surname>van der Steege</surname><given-names>G</given-names></name><name><surname>Bruinenberg</surname><given-names>M</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name><name><surname>Te Meerman</surname><given-names>GJ</given-names></name><name><surname>van der Graaf</surname><given-names>WT</given-names></name></person-group><article-title>The HLA class III subregion is responsible for an increased breast cancer risk</article-title><source>Hum Mol Gen</source><year>2003</year><volume>12</volume><fpage>2311</fpage><lpage>2319</lpage><pub-id pub-id-type="pmid">12915440</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddg245</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>E</given-names></name><name><surname>Vieira</surname><given-names>J</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>R</given-names></name><name><surname>Alves</surname><given-names>H</given-names></name><name><surname>Almeida</surname><given-names>S</given-names></name><name><surname>Rodrigues</surname><given-names>P</given-names></name><name><surname>Lacerda</surname><given-names>R</given-names></name><name><surname>Porto</surname><given-names>G</given-names></name></person-group><article-title>Involvement of the Major Histocompatibility Complex region in the genetic regulation of circulating CD8+ T-cell numbers in humans</article-title><source>Tissue Antigens</source><year>2004</year><volume>64</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15191520</pub-id><pub-id pub-id-type="doi">10.1111/j.1399-0039.2004.00245.x</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Determination of H63D mutation of the <italic>HFE </italic>gene by restriction enzyme analysis</bold>. Molecular weight marker (MW) sizes are shown on the first lane.</p></caption><graphic xlink:href="1471-2407-6-37-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Determination of C282Y mutation of the <italic>HFE </italic>gene by restriction enzyme analysis</bold>. Neither homozygote nor heterozygote C282Y mutations were found in patients or in healthy controls.</p></caption><graphic xlink:href="1471-2407-6-37-2"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>HFE mutations with nucleotide changes and their positions within <italic>HFE</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Mutation</bold></td><td align="center"><bold>Nucleotide change</bold></td><td align="center"><bold>Position relative to initiating ATG </bold>[GenBank: <ext-link ext-link-type="gen" xlink:href="U60319">U60319</ext-link>]</td><td align="center"><bold>Position <italic>in HFE</italic></bold></td></tr></thead><tbody><tr><td align="center">C282Y</td><td align="center">G &#x02192; A</td><td align="center">5473</td><td align="center">Exon 4</td></tr><tr><td align="center">H63D</td><td align="center">C &#x02192; G</td><td align="center">3513</td><td align="center">Exon 2</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Characteristics of breast cancer patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Variable</td><td align="center" colspan="2"><italic>HFE </italic>genotype</td></tr><tr><td></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center"><italic>H63D </italic>allele<sup>&#x003a8;</sup></td><td align="center"><italic>Wt/Wt</italic><sup>&#x003be;</sup></td></tr></thead><tbody><tr><td align="left">Mean age at diagnosis in years (range)</td><td align="center">42 (32&#x02013;75)</td><td align="center">40 (26&#x02013;62)</td></tr><tr><td align="left">Premenopausal at diagnosis</td><td align="center">N = 22</td><td align="center">N = 35</td></tr><tr><td align="left">Familial</td><td align="center">N = 8</td><td align="center">N = 9</td></tr><tr><td align="left">Early onset *</td><td align="center">N = 12</td><td align="center">N = 22</td></tr><tr><td align="left">Sporadic</td><td align="center">N = 31</td><td align="center">N = 40</td></tr></tbody></table><table-wrap-foot><p>&#x003a8; Heterozygous patients for H63D allele.</p><p>&#x003be; <italic>Wt/Wt</italic>, homozygous wild-type.</p><p>* Patients diagnosed at younger than 40 years.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Statistical analysis of cases with H63D mutation. Analysis between Total breast cancer patients and Healthy controls, Sporadic breast cancer patients and Healthy controls, Familial breast cancer patients and Healthy controls, Sporadic breast cancer and Familial breast cancer patients, Premenopausal and Postmenopausal breast cancer patients are shown. One healthy volunteer was homozygous for the mutation; all other subjects listed here were heterozygous. All the subjects studied were free from C282Y mutation.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Cases with H63D mutation</td><td align="left"><italic>P </italic>value<break/> (two-sided)</td><td align="left">Odds ratio (OR)</td><td align="left">%95 Confidence Interval-CI-<break/>(using the approximation of Woolf)</td></tr></thead><tbody><tr><td align="left">Total breast cancer patients: Healthy controls</td><td align="left">39/88: 28/100</td><td align="left">0.02</td><td align="left">2.05</td><td align="left">1.12 to 3.75</td></tr><tr><td align="left">Sporadic breast cancer patients: Healthy controls</td><td align="left">31/71: 28/100</td><td align="left">0.05</td><td align="left">2</td><td align="left">1.05 to 3.78</td></tr><tr><td align="left">Familial breast cancer patients: Healthy controls</td><td align="left">8/17: 28/100</td><td align="left">0.15</td><td align="left">2.29</td><td align="left">0.80 to 6.52</td></tr><tr><td align="left">Sporadic breast cancer patients: Familial breast cancer patients</td><td align="left">31/71: 8/17</td><td align="left">1</td><td align="left">1.15</td><td align="left">0.4 to 3.32</td></tr><tr><td align="left">Premenopausal breast cancer patients: Post menopausal breast cancer patients</td><td align="left">22/57: 5/7</td><td align="left">0.12</td><td align="left">0.25</td><td align="left">0.04 to 1.41</td></tr></tbody></table></table-wrap></sec></back></article> 